Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Limosilactobacillus reuteri ATCC PTA 6475
- Development stage
- Unknown
- Lead developer
- BioGaia
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Limosilactobacillus reuteri ATCC PTA 6475 (formerly classified as Lactobacillus reuteri ATCC PTA 6475) is a human-derived, patented probiotic strain originally isolated from breast milk. Developed by the Swedish probiotic company BioGaia, this strain has been extensively studied for its therapeutic potential in bone health, gastrointestinal disorders, and metabolic regulation. It is marketed under the brand name BioGaia Osfortis (often co-formulated with Vitamin D3) for the prevention of bone loss in postmenopausal women. Mechanistically, L. reuteri ATCC PTA 6475 is believed to modulate the gut-bone axis by suppressing pro-inflammatory and pro-osteoclastogenic cytokines (such as TNF-alpha and IL-6) in the intestine and bone marrow, thereby reducing osteoclastogenesis and promoting bone formation. It also produces histamine, which acts on histamine H2 receptors to suppress inflammatory responses, and has been shown to stimulate oxytocin secretion, which may influence social behavior and wound healing. Clinical trials have evaluated its efficacy in reducing bone mineral density loss in older women, mitigating glucocorticoid-induced bone impairment, and improving symptoms of irritable bowel syndrome (IBS) when used alone or in combination with other strains.
- Brand names
- BioGaia OsfortisOsfortis
- Other names
- ATCC PTA 6475ATCC PTA-6475L. reuteri ATCC PTA 6475L. reuteri ATCC PTA-6475L. reuteri MM4-1AL. reuteri OsfortisLactobacillus reuteri ATCC PTA 6475Lactobacillus reuteri ATCC PTA-6475Lactobacillus reuteri MM4-1ALimosilactobacillus reuteri ATCC PTA-6475PTA 6475PTA6475PTA-6475
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Limosilactobacillus reuteri ATCC PTA 6475.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Limosilactobacillus reuteri ATCC PTA 6475.